Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Non-Current Debt: 2021-2025

Historic Non-Current Debt for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to $107.5 million.

  • Arcutis Biotherapeutics' Non-Current Debt rose 2.29% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 2.29%. This contributed to the annual value of $107.2 million for FY2024, which is 46.88% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Non-Current Debt stood at $107.5 million for Q3 2025, which was up 0.42% from $107.0 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Non-Current Debt's 5-year high stood at $203.8 million during Q2 2024, with a 5-year trough of $72.3 million in Q4 2021.
  • For the 3-year period, Arcutis Biotherapeutics' Non-Current Debt averaged around $158.4 million, with its median value being $198.8 million (2023).
  • In the last 5 years, Arcutis Biotherapeutics' Non-Current Debt spiked by 173.35% in 2022 and then tumbled by 47.66% in 2024.
  • Arcutis Biotherapeutics' Non-Current Debt (Quarterly) stood at $72.3 million in 2021, then soared by 173.35% to $197.8 million in 2022, then climbed by 2.04% to $201.8 million in 2023, then plummeted by 46.88% to $107.2 million in 2024, then increased by 2.29% to $107.5 million in 2025.
  • Its last three reported values are $107.5 million in Q3 2025, $107.0 million for Q2 2025, and $107.6 million during Q1 2025.